Next-Gen Psilocybin

Cybin, a biotech company working on next-generation psychedelic treatments, announced remarkable results from its Phase 2 clinical trial using a proprietary version of deuterated psilocybin for the treatment of depression.

CYB003 is a next-generation psilocybin designed to provide a faster onset of action and to reduce the duration of effects, ultimately thinning the financial barrier to access of this medicine in a medical setting.

The trial’s interim data demonstrated “rapid, robust, and clinically significant reduction of depression symptoms” three weeks after a single 12mg dose of CYB003.

Read more

Podcast: Metaplasticity and Reopening Critical Periods with Psychedelics

This podcast discusses how psychedelics reopen critical periods of learning, and how the true benefit of psychedelics could be in learning how best to reopen those critical periods, how long they’re open for, and which therapeutic frameworks and integration practices could best take advantage of them.

Read more

Podcast: The Shadow Side of Psychedelics

This interview was recorded at the Psychedelic Science 2023 Conference, and discussed are the pitfalls of psychedelics:

how the nature of capitalism and returning profits to shareholders affects the concept of set and setting; how easy it is to prescribe ketamine and the puppy mill clinics popping up everywhere; how innovators are racing to the bottom to get ahead; the designer drug epidemic likely leading us to a Prozac Nation 2.0; digital narcissism, Instagram “Shamans,” and the dangers of cults; chemists trying to take the experience out of the drug; the overuse of psychedelics creating super egos; and much more.

Read more